Skip to main content

Google Scholar

NCBI Bibliography


31) Pomeroy A, Schmidt E, Sorger PK, AC Palmer (2022)
Drug independence and the curability of cancer by combination chemotherapy
Trends in Cancer


30) Plana D, Fell G, Alexander BM, Palmer AC ‡, Sorger PK ‡ (2022) ( co-corresponding)
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects
Nature Communications 13:876


29) Plana D*, Palmer AC*‡, Sorger PK‡ (2022) (*co-first, co-corresponding)
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Cancer Discovery 12: 606


28) Palmer AC, Izar B, Hwangbo H, Sorger PK (2022)
Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
Clinical Cancer Research 28:368
News in ASCO Post, AACR, AAAS EurekAlert, STAT News, MedicalXpress, In the Pipeline


27) Palmer AC*, Plana D*, Sorger PK (2020) (*equal)
Comparing the efficacy of cancer therapies between subgroups in basket trials.
Cell Systems 11:449


26) Palmer AC*, Plana D*, Gao H*, Korn JM, Yang G, Green J, Zhang X, Velazquez R, McLaughlin ME, Ruddy DA, Kowal C, Goldovitz J, Bullock C, Rivera S, Rakiec D, Elliott G, Fordjour P, Meyer R, Loo A, Kurth E, Engelman JA, Bitter H, Sellers WR, Williams JA, Sorger PK (2020) (*equal)
A proof of concept for biomarker-guided targeted therapy for ovarian cancer based on patient-derived tumor xenografts.
Cancer Research 80:4278


25) Clarelli F, Palmer AC, Singh B, Storflor M, Lauksund S, Cohen T, Abel S, Abel zur Wiesch P (2020)
Drug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones.
PLOS Computational Biology 16:e1008106


24) He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Lv D, Wiegand JS, Li W, Palmer AC, Zheng G, Weinstock DM, Zhou D (2020)
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
Journal of Hematology & Oncology 13:95


23) Chopra SS, Jenney A, Palmer AC, Niepel M, Chung M, Mills C, Sivakumaren, SC, Liu Q, Chen JY, Yapp C, Asara JM, Gray NS, Sorger PK (2020)
Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells.
Cell Systems 10:p66


22) Palmer AC*, Chidley C*, Sorger PK (2019) (*equal)
A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.
eLife 8:e50036


21) Wang H, Sheehan RP, Palmer AC, Everley RA, Boswell SA, Ron-Harel N, Holton KM, Jacobson CA, Erickson AR, Maliszewski  L, Haigis MC, Sorger PK. (2019)
Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.
Cell Systems 8:p412


20) Nan N*, Crooks M*, Palmer AC, Dodd IB, Shearwin KE. (2019)
RNA polymerase pausing at a protein roadblock can enhance transcriptional interference by promoter occlusion.
FEBS Letters 593:p903


19) Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA, Secrist JP, Drew L, Schuller A, Cidado J, Letai A, Weinstock DM (2019)
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.
Blood 133:p566
News in Blood.


18) Chabner BA, Palmer AC (2018)
Clinical Strategies for Cancer Treatment: The Role of Drugs, in
Cancer Chemotherapy, Immunotherapy and Biotherapy, 6th Ed., Wolters Kluwer Health.


17) Weinstein ZB, Kuru N, Kiriakov S, Palmer AC, Khalil AS, Clemons PA, Zaman MH, Roth FP, Cokol M. (2018)
Modeling the impact of drug interactions on therapeutic selectivity.
Nature Communications 9:p3452


16) Palmer AC, Chait R, Kishony R (2018)
Non-optimal gene expression creates latent potential for antibiotic resistance.
Molecular Biology and Evolution 35:p2669


15) Palmer AC, Sorger PK (2017)
Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy.
Cell 171:p1678
News in CellNatureHarvard Medical SchoolThe Medicine MakerBioCentury, ecancerMedicalXpress, Practical Oncology.


14) Schultz D, Palmer AC, Kishony R. (2017)
Regulatory dynamics determine cell fate following abrupt antibiotic exposure.
Cell Systems 5:p509


13) Hao N, Palmer AC, Dodd IB, Shearwin KE (2017)
Directing traffic on DNA – How transcription factors relieve or induce transcriptional interference.
Transcription 8:p120


12) Palmer AC (2016)
The many genes of drug mechanism. (News)
Nature Chemical Biology 12:p57


11) Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ (2016)
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers With CDK4/6 Inhibitors.
Cancer Cell 29:p255
News in Cancer Discovery, Cancer Cell.


10) Chait R, Palmer AC, Yelin I, Kishony R (2016)
Pervasive selection for and against antibiotic resistance in inhomogeneous multi stress environments.
Nature Communications 7:p10333


9) Hao N, Palmer AC, Ahlgren-Berg A, Shearwin KE, Dodd IB (2016)
The role of repressor kinetics in relief of transcriptional interference between convergent promoters.
Nucleic Acids Research 44:p6625


8) Palmer AC*, Toprak E*, Baym M, Kim S, Veres A, Bershtein S, Kishony R (2015) (*equal)
Delayed commitment to evolutionary fate in antibiotic resistance fitness landscapes.
Nature Communications 6:p7385


7) Palmer AC and Kishony R (2014)
Opposing effects of target overexpression reveal drug mechanisms.
Nature Communications 5:p4296


6) Palmer AC and Kishony R (2013)
Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance.
Nature Reviews Genetics 14:p243


5) Palmer AC, Egan JB, Shearwin KE (2011)
Transcriptional interference by RNA polymerase pausing and dislodgement of transcription factors.
Transcription 2:p9


4) Palmer AC, Angelino E, Kishony R (2010)
Chemical decay of an antibiotic inverts selection for resistance.
Nature Chemical Biology 6:p105
News in Nature Chemical Biology and Chemistry World.


3) Palmer AC, Ahlgren-Berg A, Egan JB, Dodd IB, Shearwin KE (2009)
Potent transcriptional interference by pausing of RNA polymerases over a downstream promoter.
Molecular Cell 34:p545


2) Palmer AC and Shearwin KE (2009)
Guidance for data collection and computational modelling of regulatory networks.
Methods in Molecular Biology 541:p337


1) Sneppen K, Dodd IB, Shearwin KE, Palmer AC, Schubert RA, Callen BP, Egan JB. (2005)
A mathematical model for transcriptional interference by RNA polymerase traffic in Escherichia coli.
Journal of Molecular Biology 18:p399